| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,204,896 | -6,768,323 |
| Depreciation | 903 | 602 |
| Non-cash lease expense for right-of-use assets | 70,677 | 46,359 |
| Stock-based compensation | 734,009 | 430,962 |
| Prepaid expenses and other | -690,228 | -745,834 |
| Operating lease liability | -66,905 | -45,073 |
| Accounts payable | -153,708 | -95,126 |
| Due from related parties | - | 0 |
| Accrued expenses | 445,075 | 684,512 |
| Net cash used in operating activities | -8,484,617 | -5,000,253 |
| Net proceeds from the sale of stock and exercise of warrants | 13,618,718 | 10,758,802 |
| Shares withheld to pay taxes on stock-based compensation | 10,404 | 10,404 |
| Payment of finance lease obligation | 6,602 | 2,850 |
| Settlement of stock award | - | 0 |
| Net cash provided by financing activities | 13,601,712 | 10,745,548 |
| Net increase (decrease) in cash and cash equivalents | 5,117,095 | 5,745,295 |
| Cash and cash equivalents at beginning of period | 1,191,325 | - |
| Cash and cash equivalents at end of period | 6,308,420 | - |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)